Levetiracetam (All indications)

Child/Infant death (> 28 days of life)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9020
R30721
Coste (Levetiracetam) (Controls unexposed, NOS), 2020 Death (Mean follow up 3-4 years) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.76 [0.57;5.49] C 3/621   4,695/1,710,441 4,698 621
ref
S8983
R30486
Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 Infant death (0–364 days of age) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 4.57 [0.18;118.16] C
excluded (control group)
0/13   1/173 1 13
ref
S8984
R30498
Artama (Levetiracetam) (Controls unexposed, disease free), 2013 Infant death (0–364 days of age) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free excluded Adjustment: No 14.01 [0.83;236.71] C
excluded (control group)
0/13   2,048/719,509 2,048 13
ref
S8985
R30510
Artama (Levetiracetam) (Controls unexposed, sick), 2013 Infant death (0–364 days of age) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No 13.00 [0.68;247.90] C 0/13   5/1,793 5 13
ref
Total 2 studies 2.96 [0.53;16.41] 4,703 634
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Coste (Levetiracetam) (Controls unexposed, NOS), 2020Coste, 2020 1 1.76[0.57; 5.49]4,69862174%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Artama (Levetiracetam) (Controls unexposed, sick), 2013Artama, 2013 2 13.00[0.68; 247.90]51326%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 35% 2.96[0.53; 16.41]4,7036340.550.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam) (Controls unexposed, NOS; 2: Levetiracetam) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.96[0.53; 16.41]4,70363435%NACoste (Levetiracetam) (Controls unexposed, NOS), 2020 Artama (Levetiracetam) (Controls unexposed, sick), 2013 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.76[0.57; 5.49]4,698621 -NACoste (Levetiracetam) (Controls unexposed, NOS), 2020 1 unexposed, sickunexposed, sick 13.00[0.68; 247.90]513 -NAArtama (Levetiracetam) (Controls unexposed, sick), 2013 1 Tags Adjustment   - No  - No 2.96[0.53; 16.41]4,70363435%NACoste (Levetiracetam) (Controls unexposed, NOS), 2020 Artama (Levetiracetam) (Controls unexposed, sick), 2013 2 All studiesAll studies 2.96[0.53; 16.41]4,70363435%NACoste (Levetiracetam) (Controls unexposed, NOS), 2020 Artama (Levetiracetam) (Controls unexposed, sick), 2013 20.550.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8983, 8984

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 3.26[0.51; 20.87]6,74663444%NACoste (Levetiracetam) (Controls unexposed, NOS), 2020 Artama (Levetiracetam) (Controls unexposed, disease free), 2013 2 unexposed, sick controlsunexposed, sick controls Out of scale13.00[0.68; 247.90]513 -NAArtama (Levetiracetam) (Controls unexposed, sick), 2013 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 4.57[0.18; 118.16]113 -NAArtama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 10.510.01.0